If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Galcanezumab is indicated in adults for the
preventive treatment of migraine, and
treatment of ECH.1
In the ECH study, the primary endpoint was overall mean change from baseline in weekly CH attack frequency across weeks 1 to 3 compared with placebo.2
The prevention of the onset of cluster periods was not a defined endpoint in the ECH study.2 As such, there are no evidence to suggest that galcanezumab prevents the onset of, or reduces the frequency of, cluster periods.
However, when dosed at the onset of a cluster period and then monthly until the end of the cluster period, galcanezumab treats ECH by reducing the frequency of CH attacks during that cluster period.2
Enclosed Prescribing Information
2. Goadsby PJ, Dodick DW, Leone M, et al. Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med. 2019;381(2):132-141. http://dx.doi.org/10.1056/NEJMoa1813440
CH = cluster headache
ECH = episodic cluster headache
Date of Last Review: January 03, 2020